Western Blot: Influenza A Virus PB2 Antibody [NBP2-42879] - Non-infected (-) and infected (+) H1299 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with Influenza A virus PB2 ...read more
Immunocytochemistry/ Immunofluorescence: Influenza A Virus PB2 Antibody [NBP2-42879] - Analysis of A/WSN/33 infected Vero cells were fixed in 4% paraformaldehyde at RT for 20 min. Green: PB2 protein stained by Influenza ...read more
Western Blot: Influenza A Virus PB2 Antibody [NBP2-42879] - Analysis of 5 ug whole cell lysate. A: DF1 B: WSN virus infected DF1 10hr 7.5% SDS PAGE diluted at 1:5000.
Use in immunoprecipitation reported in scientific literature (PMID:31810278).
86 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read Publications using NBP2-42879 in the following applications:
FAQs for Influenza A Virus PB2 Antibody (NBP2-42879). (Showing 1 - 1 of 1 FAQs).
i want to know the difference about these two produce (NBP2-42878 and NBP2-42879). only protein content?
The main difference is the immunogen used to make them. The N-terminal region of Influenza A virus PB2 was used for NBP2-42878, and the C-terminus was used for NBP2-42879. Therefore, NBP2-42878 recognizes the N-terminal region, and NBP2-42879 recognizes the C-terminal region.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Influenza A Virus PB2 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.